Avalyn Pharma Inc.
AVLN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001540171
No open-market purchases or sales by Avalyn Pharma Inc. insiders were filed in the last 90 days; 93 institutions reported holding it in 13F filings for Q2 2026, worth $1.46B in total; Soros Fund Management is the only superinvestor holding it.
Key figures
- Market capClose on Nov 9, 2026
- $1.31B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +93 vs. previous quarter
- 93
- 13F valueReported value at the end of Q2 2026
- $1.46B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, Q2 FY2026
- $2.70M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 2.35M
- Shares sold short
- Change
- −162.0K
- −6.4% vs. previous
- Days to cover
- 6.63
- At average daily volume
Superinvestors holding AVLN, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Avalyn Pharma Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
<0.1%
Avalyn Pharma Inc.'s share of the portfolio
- Shares
- 10,000
- Value
- $329.2K
Latest insider trades
See all insider tradesOpen-market purchases and sales by Avalyn Pharma Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 (view filing) | May 1 | 4 days | Novo Holdings A/S10% Owner | PPurchaseVoting Common Stock | +555.6K | $18.00 | +$10.0M | +16.7%3.88M after | |
| May 1, 2026 (view filing)6:46 PM ET | May 1 | Same day | George Simeon and 1 other10% Owner | PPurchase | +555.6K | $18.00 | +$10.0M | +98.1%1.12M after | 2 lots |
| May 1, 2026 (view filing) | May 1 | Same day | Carroll JillDirector | PPurchase | +277.8K | $18.00 | +$5.00M | +14.6%2.19M after |
Top 10 13F holders, Q2 2026
See all 93 holdersThe largest institutional positions in Avalyn Pharma Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 5,835,259 | $192.1M | 0.01% | +5,835,259 | New |
| Novo Holdings A/S | 3,883,289 | $127.8M | 7.45% | +3,883,289 | New |
| Sr One Capital Management, LP | 3,308,649 | $108.9M | 10.48% | +3,308,649 | New |
| Perceptive Advisors LLC | 2,675,296 | $88.1M | 1.37% | +2,675,296 | New |
| Suvretta Capital Management, LLC | 2,503,109 | $82.4M | 1.73% | +2,503,109 | New |
| NVP Associates, LLC | 2,268,404 | $74.7M | 22.75% | +2,268,404 | New |
| Wellington Management Group LLP | 2,201,986 | $72.5M | 0.01% | +2,201,986 | New |
| Price T Rowe Associates Inc | 1,735,231 | $57.1M | 0.01% | +1,735,231 | New |
| Catalio Capital Management, LP | 1,675,830 | $55.2M | 10.37% | +1,675,830 | New |
| T. Rowe Price Investment Management, Inc. | 1,602,745 | $52.8M | 0.03% | +1,602,745 | New |
Holders of 5% or more of AVLN
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Avalyn Pharma Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 13.20%5.84M shares | +1.70 ppfrom 11.50% | May 5, 20262 filings | Aug 6, 2026 | SEC |
| Novo Holdings A/S | 13G | 8.80%3.88M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Sr One Capital Management, LLC | 13D | 7.50%3.31M shares | New | May 8, 20261 filing | May 8, 2026 | SEC |
| Perceptive Advisors LLC | 13G | 6.00%2.68M shares | New | May 7, 20261 filing | May 7, 2026 | SEC |
| Suvretta Capital Management, LLC | 13D | 5.60%2.50M shares | New | May 8, 20261 filing | May 8, 2026 | SEC |